Table 1.

Pharmacokinetic parameters, brain concentrations, and relative brain accumulation of sorafenib after oral administration at 10 mg/kg

	Genotype
	WT	Abcb1a/1b^−/−	Abcg2^−/−	Abcb1a/1b/Abcg2^−/−
AUC_(0–6), μg/mL h	24.0 ± 4.8	19.6 ± 0.7	22.2 ± 1.5	21.2 ± 2.3
C_max, μg/mL	6.9 ± 1.3	6.7 ± 0.8	7.1 ± 0.6	6.0 ± 0.8
T_max, h	1	1	1	2
C_brain, μg/g	0.12 ± 0.04	0.11 ± 0.04	0.50 ± 0.13^*	1.04 ± 0.08^*^,^†
Fold increase	1.0	0.9	4.2	8.7
P_brain (×10⁻³ h⁻¹)	5.3 ± 2.7	5.8 ± 2.2	22.6 ± 5.0^*	49.4 ± 5.2^*^,^†
Fold increase	1.0	1.1	4.3	9.3

NOTE: AUC_(0–6), area under plasma concentration-time curve up to 6 h; C_max, maximum plasma concentration; T_max, time of maximal plasma concentration; C_brain, brain concentration at 6 h after oral administration; P_brain, relative brain accumulation at 6 h after oral administration, calculated by determining the sorafenib brain concentration relative to the AUC_0–6. Data are means ± SD (n = 5).

↵*P < 0.001, compared with WT mice.
↵^†P < 0.01, compared with Abcg2^−/− mice.